PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8856477-4 1996 We hypothesized that the contribution of ANG II to the cardiovascular response to dynamic exercise is characterized more precisely with losartan than with saralasin. Saralasin 155-164 angiotensinogen Homo sapiens 41-47 20828629-6 2010 First, the well-known retrograde amnesic effect of the angiotensin II antagonist saralasin is not due to interference on memory storage, but to modulation of memory expression. Saralasin 81-90 angiotensinogen Homo sapiens 55-69 11641660-10 2001 Intracerebroventricular angiotensin II, in the presence of saralasin, did not affect swallowing (0.6 +/- 0.1 swallows per minute) or fetal blood pressure. Saralasin 59-68 angiotensinogen Homo sapiens 24-38 11025447-8 2000 Exposure to TNF-alpha increased the concentration of ANGII in the serum-free extracellular medium by fivefold in A549 cell cultures and by 40-fold in primary AEC preparations; further, exposure to TNF-alpha for 40 h caused a net cell loss of 70%, which was completely abrogated by either the caspase inhibitor ZVAD-fmk, lisinopril, or saralasin. Saralasin 335-344 angiotensinogen Homo sapiens 53-58 10330045-11 1999 The nonselective ANG II-receptor antagonist saralasin completely abrogated both ANG II- and angiotensinogen-induced apoptosis at a concentration of 50 microgram/ml. Saralasin 44-53 angiotensinogen Homo sapiens 17-23 10330045-11 1999 The nonselective ANG II-receptor antagonist saralasin completely abrogated both ANG II- and angiotensinogen-induced apoptosis at a concentration of 50 microgram/ml. Saralasin 44-53 angiotensinogen Homo sapiens 80-86 9731749-4 1998 AII-stimulated transport was blocked by saralasin, an AII receptor antagonist, indicating that AII binding to a specific receptor is required for AII to elicit the transport response. Saralasin 40-49 angiotensinogen Homo sapiens 0-3 9731749-4 1998 AII-stimulated transport was blocked by saralasin, an AII receptor antagonist, indicating that AII binding to a specific receptor is required for AII to elicit the transport response. Saralasin 40-49 angiotensinogen Homo sapiens 54-57 9731749-4 1998 AII-stimulated transport was blocked by saralasin, an AII receptor antagonist, indicating that AII binding to a specific receptor is required for AII to elicit the transport response. Saralasin 40-49 angiotensinogen Homo sapiens 54-57 9731749-4 1998 AII-stimulated transport was blocked by saralasin, an AII receptor antagonist, indicating that AII binding to a specific receptor is required for AII to elicit the transport response. Saralasin 40-49 angiotensinogen Homo sapiens 54-57 8856477-11 1996 We conclude that the contribution of ANG II to the cardiovascular response to dynamic exercise is demonstrated more clearly with losartan than with saralasin. Saralasin 148-157 angiotensinogen Homo sapiens 37-43 8890924-7 1996 The angiotensin II-induced intracellular Ca2+ increases, PDGF production were completely abolished by saralasin and neomycin, respectively. Saralasin 102-111 angiotensinogen Homo sapiens 4-18 3381087-2 1988 To investigate the possible direct involvement of Ang II in ovulation the specific receptor antagonist of Ang II, saralasin, was administered by intraperitoneal injection to immature rats in which follide development and ovulation had been induced with pregnant mare serum gonadotrophin (PMSG) and human chorionic gonadotrophin (hCG), respectively. Saralasin 114-123 angiotensinogen Homo sapiens 106-112 7634304-8 1994 Peptide angiotensin II antagonists were first reported 20 years ago and the best studied was saralasine; they are potent and selective blockers of angiotensin II responses, but their lack of oral activity, short duration of action and the concomitant partial agonistic activity limited their clinical use. Saralasin 93-103 angiotensinogen Homo sapiens 8-22 7634304-8 1994 Peptide angiotensin II antagonists were first reported 20 years ago and the best studied was saralasine; they are potent and selective blockers of angiotensin II responses, but their lack of oral activity, short duration of action and the concomitant partial agonistic activity limited their clinical use. Saralasin 93-103 angiotensinogen Homo sapiens 147-161 8268887-1 1993 Acute blockade of the renin-angiotensin system with the parenterally active angiotensin II antagonist saralasin has been shown to effectively lower blood pressure in a large fraction of patients with essential hypertension and to improve hemodynamics in some patients with congestive heart failure. Saralasin 102-111 angiotensinogen Homo sapiens 76-90 1385427-5 1992 Concomitant treatment with saralasin, a competitive inhibitor of angiotensin II, prevented the stimulation observed with angiotensin II. Saralasin 27-36 angiotensinogen Homo sapiens 65-79 1385427-5 1992 Concomitant treatment with saralasin, a competitive inhibitor of angiotensin II, prevented the stimulation observed with angiotensin II. Saralasin 27-36 angiotensinogen Homo sapiens 121-135 2194806-5 1990 This activity appeared within 1 min of exposure to angiotensin II, and was blocked by saralasin, an angiotensin II antagonist. Saralasin 86-95 angiotensinogen Homo sapiens 51-65 2194806-5 1990 This activity appeared within 1 min of exposure to angiotensin II, and was blocked by saralasin, an angiotensin II antagonist. Saralasin 86-95 angiotensinogen Homo sapiens 100-114 2645059-4 1989 Inhibition of angiotensin II effect with saralasin (10 micrograms/kg/min) or angiotensin II production with captopril (2 mg/kg) lowered systemic resistance (Rs) by 14% and 34%, respectively (p less than 0.05), and raised pulmonary resistance (Rp) by 35% and 77%, respectively (p less than 0.05). Saralasin 41-50 angiotensinogen Homo sapiens 14-28 7884581-1 1994 BACKGROUND: Acute blockade of the renin-angiotensin system with the parenterally active angiotensin II antagonist saralasin has been shown to effectively lower blood pressure in a large fraction of patients with essential hypertension and to improve haemodynamics in some patients with congestive heart failure. Saralasin 114-123 angiotensinogen Homo sapiens 88-102 1942082-3 1991 The inotropic effect of AII was markedly inhibited by 1 microM saralasin or 1 microM diltiazem. Saralasin 63-72 angiotensinogen Homo sapiens 24-27 2211876-3 1990 Nanomolar concentrations of saralasin (a partial Ang II agonist) stimulated brain microvessel endothelial cell endocytosis by 30% whereas Ang II treatment enhanced Lucifer yellow uptake by 20%. Saralasin 28-37 angiotensinogen Homo sapiens 49-55 500810-5 1979 The AII competitive inhibitor, saralasin (0.3-30 mug/kg per min) was then infused to study the occurrence of angiotensinogenic hypertension in both HREH subgroups. Saralasin 31-40 angiotensinogen Homo sapiens 4-7 6202006-8 1984 Renin secretion is very significantly reduced by beta-blocking agents (propranolol); conversion of angiotensin I into angiotensin II is inhibited by teprotide, captopril and their derivatives; peripheral actions of angiotensin II are blocked by saralasin. Saralasin 245-254 angiotensinogen Homo sapiens 99-112 6202006-8 1984 Renin secretion is very significantly reduced by beta-blocking agents (propranolol); conversion of angiotensin I into angiotensin II is inhibited by teprotide, captopril and their derivatives; peripheral actions of angiotensin II are blocked by saralasin. Saralasin 245-254 angiotensinogen Homo sapiens 118-132 6202006-8 1984 Renin secretion is very significantly reduced by beta-blocking agents (propranolol); conversion of angiotensin I into angiotensin II is inhibited by teprotide, captopril and their derivatives; peripheral actions of angiotensin II are blocked by saralasin. Saralasin 245-254 angiotensinogen Homo sapiens 215-229 6367901-3 1984 In addition, angiotensin II blockade with saralasin was used in an attempt to treat hypertension during CPB. Saralasin 42-51 angiotensinogen Homo sapiens 13-27 6993602-2 1980 A significant relationship between the changes in MAP during treatment with saralasin and captopril with the pretreatment levels of PRA, active and total PRC and angiotensin II were found; while the pre-existing level of inactive renin was not a predictor for the hypotensive effect of saralasin and captopril. Saralasin 76-85 angiotensinogen Homo sapiens 162-176 479350-3 1979 Saralasin (10(-8) M) caused a partial but significant inhibition of AII-stimulated 18-OHDOC production, while 10(-6) M saralasin blocked AII-stimulated steroidogenesis completely. Saralasin 0-9 angiotensinogen Homo sapiens 68-71 479350-3 1979 Saralasin (10(-8) M) caused a partial but significant inhibition of AII-stimulated 18-OHDOC production, while 10(-6) M saralasin blocked AII-stimulated steroidogenesis completely. Saralasin 119-128 angiotensinogen Homo sapiens 137-140 479350-5 1979 The direct AII effect on 18-OHDOC secretion and the antagonistic effect of saralasin on both exogenous and endogenous AII-stimulated steroidogenesis, documented in these experiments, indicate that the increase in 18-OHDOC levels after sodium restriction reported in man is probably mediated by the renin-angiotensin system. Saralasin 75-84 angiotensinogen Homo sapiens 118-121 3905045-4 1985 This activity appeared within 1 minute of exposure to angiotensin II, and was blocked by saralasin, an angiotensin II antagonist. Saralasin 89-98 angiotensinogen Homo sapiens 54-68 3905045-4 1985 This activity appeared within 1 minute of exposure to angiotensin II, and was blocked by saralasin, an angiotensin II antagonist. Saralasin 89-98 angiotensinogen Homo sapiens 103-117 6328965-3 1984 As a pharmacologic estimate of angiotensin II receptor activity, we infused the angiotensin II analogue, saralasin, in 20 patients with severe chronic congestive heart failure (CHF). Saralasin 105-114 angiotensinogen Homo sapiens 80-94 6328965-6 1984 Both converting enzyme inhibition with captopril and sodium repletion, factors known to decrease endogenous angiotensin II activity, provoked agonist responses to saralasin infusion. Saralasin 163-172 angiotensinogen Homo sapiens 108-122 6168855-0 1981 Systemic hemodynamic and hormonal responses during angiotensin II blockade with saralasin. Saralasin 80-89 angiotensinogen Homo sapiens 51-65 7017596-3 1981 Injection, after sodium depletion, of saralasin, a competitive angiotensin II inhibitor, resulted in significant fall of the mean arterial pressure. Saralasin 38-47 angiotensinogen Homo sapiens 63-77 7330605-3 1981 The study was repeated 30 min after intravenous administration of dihydralazine (0.1 mg/kg body weight) in 14 subjects (group A) and during continuous infusion of the angiotensin II blocking agent Saralasin (5 micrograms/kg . Saralasin 197-206 angiotensinogen Homo sapiens 167-181 222622-6 1979 Experiments that employed the blockers saralasin, a competitive inhibitor of AII, and SQ 20881, a converting enzyme blocker, are presented; results suggest that endogenous AII is involved in the control of thirst and peripheral hormone levels. Saralasin 39-48 angiotensinogen Homo sapiens 77-80 222622-6 1979 Experiments that employed the blockers saralasin, a competitive inhibitor of AII, and SQ 20881, a converting enzyme blocker, are presented; results suggest that endogenous AII is involved in the control of thirst and peripheral hormone levels. Saralasin 39-48 angiotensinogen Homo sapiens 172-175 36260-1 1979 Simultaneous hemodynamic and blood gas measurements were performed in 26 hypertensive adults, who were cigarette smokers, before and after a 30-minute infusion of saralasin (5 microgram/kg/min) which is a highly specific competitive antagonist of angiotensin II (AII). Saralasin 163-172 angiotensinogen Homo sapiens 247-261 36260-1 1979 Simultaneous hemodynamic and blood gas measurements were performed in 26 hypertensive adults, who were cigarette smokers, before and after a 30-minute infusion of saralasin (5 microgram/kg/min) which is a highly specific competitive antagonist of angiotensin II (AII). Saralasin 163-172 angiotensinogen Homo sapiens 263-266 289860-0 1979 Angiotensin II profiling with saralasin: summary of Eaton collaborative study. Saralasin 30-39 angiotensinogen Homo sapiens 0-14 289867-0 1979 Angiotensin II blockade by saralasin in the evaluation of hypertension in children. Saralasin 27-36 angiotensinogen Homo sapiens 0-14 215414-3 1978 Prior administration of Saralasin, an angiotensin receptor antagonist, caused significant attenuation of the pressor action of angiotensin II, and also significantly antagonized the facilitatory effect of angiotensin II on sympathetic transmission to the myocardium. Saralasin 24-33 angiotensinogen Homo sapiens 127-141 215414-3 1978 Prior administration of Saralasin, an angiotensin receptor antagonist, caused significant attenuation of the pressor action of angiotensin II, and also significantly antagonized the facilitatory effect of angiotensin II on sympathetic transmission to the myocardium. Saralasin 24-33 angiotensinogen Homo sapiens 205-219 686905-1 1978 Five of 11 normotensive patients with congestive heart failure responded to an infusion of the specific angiotensin II antagonist, saralasin, by reducing systemic vascular resistance from 2274 +/- 418 to 1690 +/- 351 dynes/sec/cm-5 (mean +/- standard error). Saralasin 131-140 angiotensinogen Homo sapiens 104-118 101176-0 1978 [Arterial hypertension and maintenance hemodialysis: effects of specific inhibition of angiotensin II by saralasin acetate]. Saralasin 105-122 angiotensinogen Homo sapiens 87-101 634129-0 1978 [Anti-hypertensive effect of the angiotensin II antagonist saralasin acetate, a diagnostic criterion of renovascular hypertension]. Saralasin 59-76 angiotensinogen Homo sapiens 33-47 643579-1 1978 We have studied the effects of intravenous infusion of saralasin, a competitive antagonist of angiotensin II, in 27 hypertensive patients: 13 had essential hypertension, 14 had renal lesions which involved the renal artery in 9 cases. Saralasin 55-64 angiotensinogen Homo sapiens 94-108 577978-2 1977 A patient with intractable congestive cardiac failure secondary to renovascular hypertension and severe coronary artery disease was infused with the competitive antagonist of angiotensin II, saralasin acetate. Saralasin 191-208 angiotensinogen Homo sapiens 175-189 15405-3 1977 Competitive inhibition of angiotensin II by Saralasin does not abolish the pressor effect of catecholamines. Saralasin 44-53 angiotensinogen Homo sapiens 26-40 19645-0 1977 [Hemodynamic changes after angiotensin II blockade by saralasin (author"s transl)]. Saralasin 54-63 angiotensinogen Homo sapiens 27-41 191849-1 1976 Drinking elicited by administering angiotensin II (ANG II) to the preoptic region with cannulae passing through the lateral ventricles was attenuated significantly when the ventricles or subfornical organ were pretreated with saralasin acetate (Sar1-Ala8-angiotensin II). Saralasin 226-243 angiotensinogen Homo sapiens 35-49 191849-1 1976 Drinking elicited by administering angiotensin II (ANG II) to the preoptic region with cannulae passing through the lateral ventricles was attenuated significantly when the ventricles or subfornical organ were pretreated with saralasin acetate (Sar1-Ala8-angiotensin II). Saralasin 226-243 angiotensinogen Homo sapiens 51-57 1000214-0 1976 Angiotensin II blockade with saralasin. Saralasin 29-38 angiotensinogen Homo sapiens 0-14 985072-6 1976 An angiotensin II antagonist, saralasin acetate, used in six patients before operation in an attempt to identify those whose hypertension depended on angiotensin II activity, produced a depressor response correlating well with the surgical result. Saralasin 30-47 angiotensinogen Homo sapiens 3-17 985072-6 1976 An angiotensin II antagonist, saralasin acetate, used in six patients before operation in an attempt to identify those whose hypertension depended on angiotensin II activity, produced a depressor response correlating well with the surgical result. Saralasin 30-47 angiotensinogen Homo sapiens 150-164 191849-1 1976 Drinking elicited by administering angiotensin II (ANG II) to the preoptic region with cannulae passing through the lateral ventricles was attenuated significantly when the ventricles or subfornical organ were pretreated with saralasin acetate (Sar1-Ala8-angiotensin II). Saralasin 226-243 angiotensinogen Homo sapiens 255-269 4368826-0 1974 Inhibitory effects of central hypertensive activity of angiotensin I and II by 1-sar-8-ala-angiotensin II (saralasin acetate). Saralasin 107-124 angiotensinogen Homo sapiens 55-105 1071404-1 1976 Patients with essential hypertension were sodium deprived by five days on a 10 mM sodium diet and were then infused with an incremental infusion of saralasin, a competitive inhibitor of angiotensin II. Saralasin 148-157 angiotensinogen Homo sapiens 186-200 954592-1 1976 Infusion of the angiotensin-II-antagonist saralasine led in one patient with Bartter"s syndrome and one patient with decompensated hepatic cirrhosis, both of whom had a markedly raised plasma renin activity, to a fall in systolic and diastolic blood pressure. Saralasin 42-52 angiotensinogen Homo sapiens 16-30 1020761-2 1976 Observation of a clear-cut, supranormal decrease in blood pressure during the intravenous infusion of the angiotensin II antagonist, saralasin, has provided a far more reliable indication of the presence of an angiotensinogenic component in the hypertension. Saralasin 133-142 angiotensinogen Homo sapiens 106-120